

CAPITAL MANAGEMENT INITIATIVES

KEY HIGHLIGHTS:

- **Capital management initiatives to be put to investors at a General Meeting**
- **Consolidation of capital on a one share for every 10 shares held basis**
- **Introduction of a Less than Marketable Share Parcel Facility**
- **Notice of Meeting to be issued shortly**

15 March, 2017 Melbourne, Australia.

Australian based respiratory company Rhinomed Limited (ASX:RNO) today announced that it intends to issue a Notice of Meeting to hold a General Meeting of Members to approve a capital management initiative. The initiative will seek to consolidate the company's capital on the basis of one share for every 10 shares held, and adjust the company's constitution allowing for the sale of less than marketable parcels to be put in place.

Consolidation of capital

As part of the company's capital management program to position Rhinomed with international investors, the company proposes to consolidate its 936 million issued securities to 93.6 million (after \$0.018 placement) via a consolidation process. This is a consolidation of one share for every ten shares held. Further details, including the timetable of the consolidation will be provided in a Notice of Meeting that will be issued to all shareholders following approval by the ASX.

Facility for the sale of less than marketable parcels

The company values all of its shareholders, however it incurs significant administrative costs maintaining a large number of less than marketable parcels. As a result the company proposes to alter its constitution at the forthcoming General Meeting to allow the sale of "less than marketable parcels". Upon approval by shareholders, a facility will be put in place to coordinate this sale of unmarketable parcels. This facility will enable the company to reduce administrative costs and also provide an opportunity to investors with small holdings, who may find it difficult or expensive to dispose of those shares through normal means to dispose of their small holdings in a cost effective manner.

Further details will be issued in the Notice of Meeting shortly.

Media Enquiries

Michael Johnson, CEO & Director

+61 (0)3 8416 0900

mjohnson@rhinomed.global

Follow us on **Twitter** @rhinomedceo and @mutesnoring and @theturbinecom

RHINOMED

MAKE EVERY BREATH COUNT

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global